T-cell immuno-oncology
Human PBMC-engrafted systems for programs where human T-cell biology is central to the pharmacology question.
HUMANIZED IMMUNE MODEL
PBMC Humanized Mouse Models
Human PBMC engraftment in NOG-family mice provides a human immune-cell context for T-cell-focused immuno-oncology research and preclinical pharmacology.
The documented platform includes NOG, NOG-b2m-ko, and NOG-dKO backgrounds and emphasizes donor selection, GvHD behavior, and study-window considerations.
MODEL OVERVIEW
PBMC humanization for rapid T-cell-focused studies.
The reviewed platform describes huPBMC immune-system reconstruction with multiple NOG backgrounds. NOG-dKO is presented as a strategy to reduce GvHD-related constraints and non-specific T-cell expansion relative to conventional NOG backgrounds.
Therapeutic areaImmuno-oncology
SpeciesMouse
Host platformsNOG, b2m-ko, dKO
Typical useT-cell pharmacology
TYPICAL APPLICATIONS
What this model can support.
Humanized efficacy studies
Pair human immune-system reconstruction with project-appropriate tumor or pharmacology study designs when technically feasible.
Donor-informed study design
PBMC donor characteristics and source documentation can be incorporated into model planning and cohort selection.
GvHD-window management
Host background is selected with the intended study window and GvHD behavior in mind.
COMMON READOUTS
Readouts selected around the study question.
Endpoints are finalized with the selected model, species or strain, treatment design, and partner laboratory before study placement.
Engraftment
Protocol-defined human immune-cell reconstruction and longitudinal monitoring.
GvHD
GvHD scoring and survival can be used to characterize the available study window.
Immune profiling
Human immune-cell populations and activation-related readouts selected for the program.
Pharmacology
Model-specific efficacy or pharmacodynamic endpoints when incorporated into the study design.
Donor, host background, engraftment criteria, study window, tumor pairing, and immune-monitoring package are confirmed during technical review.
STUDY DESIGN
Key factors aligned before execution.
- NOG-family host background
- PBMC donor characteristics and availability
- Required study window
- Expected GvHD behavior
- Tumor or pharmacology context
- Flow-cytometry and biomarker endpoints
Discuss Your Program
Share the compound, mechanism, development question, preferred model, and intended endpoints. We can review fit, feasibility, and the appropriate partner-laboratory route for a PBMC Humanized study.Required fields are marked with an asterisk(*).